Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia

Wang, Danni; Ikemura, Kenji; Hasegawa, Tsubasa; Yamane, Fumihiro; Okuda, Masahiro

doi:https://doi.org/10.1016/j.biopha.2024.116801

Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia

Wang, Danni; Ikemura, Kenji; Hasegawa, Tsubasa et al.

Biomedicine and Pharmacotherapy, 2024, 175, 116801

アクセス数:136件（2025-06-16 12:38 集計）

固定URL: https://hdl.handle.net/11094/97228

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
BiomedPharmacother_175_116801	pdf	なし	1.63 MB	64	2024.07.22

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia
著者	著者名 Wang, Danni
	NRID 1000070513935 1000070513935 ORCID 0000-0003-1870-9571 0000-0003-1870-9571 researchmap permalink Kenji_Ikemura Kenji_Ikemura Scopus Author ID 36783115100 36783115100 著者名 Ikemura, Kenji
	著者名 Hasegawa, Tsubasa
	著者名 Yamane, Fumihiro
	NRID 1000070252426 1000070252426 researchmap permalink read0042639 read0042639 Scopus Author ID 56856467300 56856467300 著者名 Okuda, Masahiro
キーワード等	Human organic anion transporter 3
	Lansoprazole
	Linezolid
	PNU-142586
	Thrombocytopenia
内容	Wang D., Ikemura K., Hasegawa T., et al. Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia. Biomedicine and Pharmacotherapy 175, 116801 (2024); https://doi.org/10.1016/j.biopha.2024.116801.
抄録	Thrombocytopenia, a common adverse effect of linezolid, often occurs in patients lacking typical risk factors. In this study, we investigated the key risk factors for linezolid-induced thrombocytopenia using two real-world clinical databases and explored its underlying mechanism through in vitro and in vivo experiments. In a retrospective analysis of 150 linezolid-treated patients, multivariate analysis identified coadministration of lansoprazole, a proton pump inhibitor, as a significant independent risk factor for thrombocytopenia (odds ratio: 2.33, p = 0.034). Additionally, analysis of the Food and Drug Administration Adverse Event Reporting System database revealed a reporting odds ratio of thrombocytopenia for lansoprazole of 1.64 (95% CI: 1.25–2.16). In vitro studies showed that the uptake of PNU-142586, a major linezolid metabolite, was significantly higher in human organic anion transporter 3-expressing HEK293 (HEK-hOAT3) cells compared to HEK-pBK cells. The apparent IC50 value of lansoprazole against hOAT3-mediated transport of PNU-142586 was 0.59 ± 0.38 µM. In a pharmacokinetic study using rats, coadministration of linezolid with lansoprazole intravenously resulted in approximately a 1.7-fold increase in the area under the plasma concentration-time curve of PNU-142586, but not linezolid and PNU-142300. Moreover, PNU-142586, but not linezolid, exhibited concentration-dependent cytotoxicity in a human megakaryocytic cell line. These findings suggest that linezolid-induced thrombocytopenia should be due to delayed elimination of PNU-142586. Furthermore, delayed elimination of PNU-142586 due to renal failure and hOAT3-mediated transport inhibition by lansoprazole should exacerbate linezolid-induced thrombocytopenia.
出版者	Elsevier Masson s.r.l.
収録物名	Biomedicine and Pharmacotherapy
巻(号)	175
ページ	116801
刊行年月	2024-06-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/97228
PISSN	07533322
eISSN	19506007
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.biopha.2024.116801
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Biomedicine and Pharmacotherapy. 2024, 175, p. 116801
DC.title	Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia
DC.creator	Wang, Danni
	Ikemura, Kenji
	Hasegawa, Tsubasa
	Yamane, Fumihiro
	Okuda, Masahiro
DC.publisher	Elsevier Masson s.r.l.
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-06-01
DC.identifier	https://doi.org/10.1016/j.biopha.2024.116801
DC.subject	Human organic anion transporter 3
	Lansoprazole
	Linezolid
	PNU-142586
	Thrombocytopenia
DC.description	Wang D., Ikemura K., Hasegawa T., et al. Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia. Biomedicine and Pharmacotherapy 175, 116801 (2024); https://doi.org/10.1016/j.biopha.2024.116801.
DCTERMS.abstract	Thrombocytopenia, a common adverse effect of linezolid, often occurs in patients lacking typical risk factors. In this study, we investigated the key risk factors for linezolid-induced thrombocytopenia using two real-world clinical databases and explored its underlying mechanism through in vitro and in vivo experiments. In a retrospective analysis of 150 linezolid-treated patients, multivariate analysis identified coadministration of lansoprazole, a proton pump inhibitor, as a significant independent risk factor for thrombocytopenia (odds ratio: 2.33, p = 0.034). Additionally, analysis of the Food and Drug Administration Adverse Event Reporting System database revealed a reporting odds ratio of thrombocytopenia for lansoprazole of 1.64 (95% CI: 1.25–2.16). In vitro studies showed that the uptake of PNU-142586, a major linezolid metabolite, was significantly higher in human organic anion transporter 3-expressing HEK293 (HEK-hOAT3) cells compared to HEK-pBK cells. The apparent IC50 value of lansoprazole against hOAT3-mediated transport of PNU-142586 was 0.59 ± 0.38 µM. In a pharmacokinetic study using rats, coadministration of linezolid with lansoprazole intravenously resulted in approximately a 1.7-fold increase in the area under the plasma concentration-time curve of PNU-142586, but not linezolid and PNU-142300. Moreover, PNU-142586, but not linezolid, exhibited concentration-dependent cytotoxicity in a human megakaryocytic cell line. These findings suggest that linezolid-induced thrombocytopenia should be due to delayed elimination of PNU-142586. Furthermore, delayed elimination of PNU-142586 due to renal failure and hOAT3-mediated transport inhibition by lansoprazole should exacerbate linezolid-induced thrombocytopenia.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	97228
citation_title	Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia
citation_author	Wang, Danni
	Ikemura, Kenji
	Hasegawa, Tsubasa
	Yamane, Fumihiro
	Okuda, Masahiro
citation_publisher	Elsevier Masson s.r.l.
citation_language	英語
citation_date	2024-06-01
citation_journal_title	Biomedicine and Pharmacotherapy
citation_volume	175
citation_firstpage	116801
citation_doi	https://doi.org/10.1016/j.biopha.2024.116801
citation_public_url	https://hdl.handle.net/11094/97228

Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia

閲覧可能ファイル

論文情報

論文詳細を表示